Anti-Human PD-L1 Recombinant Antibody (SP142) (HV974073)

Name: Anti-Human PD-L1 Recombinant Antibody (SP142)
Brand: abinScience
SKU: HV974073
Price: 110 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

20ug
50ug
100ug
1mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.

HV974073

Species reactivity

Human

Applications

IHC, WB

Host species

Mouse

Clonality

Monoclonal

Isotype

IgG2a

Clone ID

SP142

Target

B7 homolog 1, B7-H1, B7H1, CD274, PD-L1, PDCD1 ligand 1, PDCD1L1, PDCD1LG1, PDL1, Programmed cell death 1 ligand 1, Programmed death ligand 1

Endotoxin level

< 10 EU/mg

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q9NZQ7

Form

Liquid

Storage buffer

0.01M PBS pH 7.4.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Product Usage Information

Application	Dilution
WB	1:500-1:2000

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Background

Programmed cell death 1 ligand 1 (CD274/PD-L1) is a ~33 kDa protein. Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis. CD274 is the therapeutic target of atezolizumab (Tecentriq) and durvalumab (Imfinzi).

1. Freeman, GJ. et al. (2000) The Journal of experimental medicine 192, 1027-34. PMID: 11015443

2. Mezzadra, R. et al. (2017) Nature 549, 106-110. PMID: 28813410

3. Burr, ML. et al. (2017) Nature 549, 101-105. PMID: 28813417

4. Huang, X. et al. (2019) Cancer immunology research 7, 1580-1590. PMID: 31399419

5. Kennedy, A. et al. (2023) The EMBO journal 42, e111556. PMID: 36727298

6. Dong, H. et al. (1999) Nature medicine 5, 1365-9. PMID: 10581077

7. Hou, J. et al. (2020) Nature cell biology 22, 1264-1275. PMID: 32929201

Note

For research use only.

Images